Global bioprocess monitoring market is anticipated to grow at a CAGR of 8.4% during the forecast period (2024-2031). The market growth is attributed in large part to the growing adoption of biopharmaceuticals and biotechnology processes. As a result, there is a growing need for more reliable and accurate bioprocess monitoring instruments. Examples of these products include vaccines, recombinant proteins, and monoclonal antibodies. As the demand for biopharmaceuticals, vaccines, and biologics continues to rise, there is a corresponding need for efficient and reliable bioprocess monitoring solutions to ensure product quality, consistency, and regulatory compliance.
Browse the full report description of “Bioprocess Monitoring Market Size, Share & Trends Analysis Report by Product (Reagents & Kits, Instruments and Software), by Application (Host Cell Residual DNA/Protein Quantitation, Mycoplasma Detection, Viral Titer Determination, and Adventitious Virus Testing), and by End-Use (Pharmaceutical & Biotechnology Companies, CROs & CMOs, and Academic & Research Institutes), Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/bioprocess-monitoring-market
In January 2024, the multinational biopharmaceutical leader AbbVie announced a substantial investment of $223.0 million into its manufacturing facility in Singapore, aimed at enhancing its capabilities in biologics manufacturing. This strategic move reflects AbbVie's commitment to advancing its production infrastructure to meet the growing demand for biologics and novel treatments. Amidst a landscape marked by increased R&D activity and stringent regulatory requirements, pharmaceutical firms are prioritizing investments in manufacturing capacity and regulatory compliance. AbbVie's investment underscores the industry's collective efforts to bring innovative biological therapies to market, reinforcing its position as a key player in the biopharmaceutical sector.
In August 2022, Beckman Coulter Life Sciences and Flownamics joined forces in a strategic partnership aimed at developing an advanced, automated solution for the real-time monitoring and control of bioprocess cultures. This collaboration merges Beckman Coulter's Vi-CELL BLU Cell Viability Analyzer with Flownamics' Seg-Flow S3 Automated On-Line system, to elevate the precision and efficiency of bioprocess monitoring. The partnership underscores a shared commitment to innovation in bioprocessing technology, leveraging complementary expertise to address the evolving needs of the biopharmaceutical industry.
Market Coverage
• The market number available for – 2023-2031
• Base year- 2023
• Forecast period- 2024-2031
• Segment Covered-
o By Product
o By Application
o By End-Use
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Maravai LifeSciences, Merck KGaA, and Bio-Techne, among others.
Key questions addressed by the report.
Global Bioprocess Monitoring Market Report Segment
By Product
By Application
By End-Use
Global Bioprocess Monitoring Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/bioprocess-monitoring-market